Anneke M. Westermann

6.4k total citations
77 papers, 1.5k citations indexed

About

Anneke M. Westermann is a scholar working on Oncology, Obstetrics and Gynecology and Reproductive Medicine. According to data from OpenAlex, Anneke M. Westermann has authored 77 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 34 papers in Oncology, 26 papers in Obstetrics and Gynecology and 26 papers in Reproductive Medicine. Recurrent topics in Anneke M. Westermann's work include Endometrial and Cervical Cancer Treatments (26 papers), Ovarian cancer diagnosis and treatment (25 papers) and Colorectal Cancer Treatments and Studies (9 papers). Anneke M. Westermann is often cited by papers focused on Endometrial and Cervical Cancer Treatments (26 papers), Ovarian cancer diagnosis and treatment (25 papers) and Colorectal Cancer Treatments and Studies (9 papers). Anneke M. Westermann collaborates with scholars based in Netherlands, United States and United Kingdom. Anneke M. Westermann's co-authors include Sjoerd Rodenhuis, Jos H. Beijnen, Wouter H. Moolenaar, Friso R. Postma, Otilia Dalesio, Jacobus van der Velden, Marrije R. Buist, Isabelle Ray‐Coquard, Lukas J.A. Stalpers and Jan H. Schornagel and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Anneke M. Westermann

76 papers receiving 1.5k citations

Peers

Anneke M. Westermann
Danhua Shen China
Ingrid Boere Netherlands
John V. Brown United States
Roisin E. O’Cearbhaill United States
Jaya Ghosh India
Charles A. Kunos United States
Amita Maheshwari India
R.P. Symonds United Kingdom
Sanaz Javadi United States
Anton Scharl Germany
Danhua Shen China
Anneke M. Westermann
Citations per year, relative to Anneke M. Westermann Anneke M. Westermann (= 1×) peers Danhua Shen

Countries citing papers authored by Anneke M. Westermann

Since Specialization
Citations

This map shows the geographic impact of Anneke M. Westermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anneke M. Westermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anneke M. Westermann more than expected).

Fields of papers citing papers by Anneke M. Westermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anneke M. Westermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anneke M. Westermann. The network helps show where Anneke M. Westermann may publish in the future.

Co-authorship network of co-authors of Anneke M. Westermann

This figure shows the co-authorship network connecting the top 25 collaborators of Anneke M. Westermann. A scholar is included among the top collaborators of Anneke M. Westermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anneke M. Westermann. Anneke M. Westermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Vermij, Lisa, Alicia León‐Castillo, Melanie Powell, et al.. (2024). Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low. Journal of Clinical Oncology. 43(4). 443–452. 3 indexed citations
2.
Vergote, Ignace, Antonio González-Martı́n, Keiichi Fujiwara, et al.. (2023). LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. Annals of Oncology. 34. S1276–S1277. 24 indexed citations
3.
Fujiwara, Keiichi, Brian M. Slomovitz, Antonio González-Martı́n, et al.. (2023). 288MO InnovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer. Annals of Oncology. 34. S1586–S1586. 4 indexed citations
4.
Vergote, Ignace, Mansoor Raza Mirza, Jalid Sehouli, et al.. (2022). 2022-RA-1548-ESGO Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: addition of a new cohort using first-line tisotumab vedotin + pembrolizumab + carboplatin ± bevacizumab in recurrent/metastatic cervical cancer. International Journal of Gynecological Cancer. 32. A64–A64. 1 indexed citations
5.
Zecha, Judith A. E. M., Judith E. Raber‐Durlacher, Alexa M. G. A. Laheij, et al.. (2022). The Potential Contribution of Dental Foci and Oral Mucositis to Febrile Neutropenia in Patients Treated With Myelosuppressive Chemotherapy for Solid Tumors and Lymphoma. SHILAP Revista de lepidopterología. 3. 940044–940044. 9 indexed citations
6.
Westermann, Anneke M., et al.. (2020). PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. Critical Reviews in Oncology/Hematology. 152. 102973–102973. 39 indexed citations
7.
Westermann, Anneke M., Heinz‐Josef Klümpen, Joanne Verheij, et al.. (2018). Two Cases of Hepatoblastoma in Young Adults. Journal of Adolescent and Young Adult Oncology. 7(3). 404–408. 4 indexed citations
8.
Léary, Alexandra, Michael Quinn, Keiichi Fujiwara, et al.. (2016). Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup (GCIG): clinical trial design for rare ovarian tumours. Annals of Oncology. 28(4). 718–726. 31 indexed citations
9.
Sehouli, Jalid, Klaus Pietzner, Pauline Wimberger, et al.. (2014). Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study. Medical Oncology. 31(8). 76–76. 14 indexed citations
10.
Amant, Frédéric, Anne Floquet, Michael Friedländer, et al.. (2014). Gynecologic Cancer InterGroup (GCIG) Consensus Review for Endometrial Stromal Sarcoma. International Journal of Gynecological Cancer. 24(9 Suppl 3). S67–S72. 61 indexed citations
11.
Goede, Valentin, Paula Cramer, R. Busch, et al.. (2014). Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials. Haematologica. 99(6). 1095–1100. 72 indexed citations
12.
Roszak, A., Mariusz Bidziński, Tudor–Eliade Ciuleanu, et al.. (2009). Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Annals of Oncology. 20(11). 1794–1802. 56 indexed citations
13.
Westermann, Anneke M., Ellen L. Jones, Baard‐Christian Schem, et al.. (2005). First results of triple‐modality treatment combining radiotherapy, chemotherapy, and hyperthermia for the treatment of patients with Stage IIB, III, and IVA cervical carcinoma. Cancer. 104(4). 763–770. 91 indexed citations
14.
Vörding, Paul J. Zum Vörde Sive, et al.. (2004). Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer. Gynecologic Oncology. 95(3). 680–685. 17 indexed citations
15.
Westermann, Anneke M., G. Wiedemann, Elke Jäger, et al.. (2003). A Systemic Hyperthermia Oncologic Working Group Trial. Oncology. 64(4). 312–321. 23 indexed citations
16.
Westermann, Anneke M., et al.. (2000). Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy. Cancer Chemotherapy and Pharmacology. 46(1). 57–62. 6 indexed citations
17.
18.
Westermann, Anneke M., L. van Leeuwen, Emanuel J.M. Willemse, et al.. (1999). At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Annals of Oncology. 10(5). 511–518. 29 indexed citations
19.
Havenaar, Johan M., et al.. (1997). Health effects of the Chernobyl disaster: illness or illness behavior? A comparative general health survey in two former Soviet regions.. Environmental Health Perspectives. 105(suppl 6). 1533–1537. 53 indexed citations
20.
Westermann, Anneke M., R. Dubbelman, Wouter H. Moolenaar, Jos H. Beijnen, & Sjoerd Rodenhuis. (1997). Successful intraperitoneal suramin treatment of peritoneal mesothelioma. Annals of Oncology. 8(8). 801–802. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Danhua Shen Breakdown of academic impact, for papers by Ingrid Boere Breakdown of academic impact, for papers by John V. Brown Breakdown of academic impact, for papers by Roisin E. O’Cearbhaill Breakdown of academic impact, for papers by Jaya Ghosh Breakdown of academic impact, for papers by Charles A. Kunos Breakdown of academic impact, for papers by Amita Maheshwari Breakdown of academic impact, for papers by R.P. Symonds Breakdown of academic impact, for papers by Sanaz Javadi Breakdown of academic impact, for papers by Anton Scharl
Rankless by CCL
2026